부산대학교 도서관

Aims: To develop a quantitative systems pharmacology model to describe the effect of dapagliflozin (a sodium‐glucose co‐transporter‐2 [SGLT2] inhibitor) on glucose‐insulin dynamics in type 2 diabetes mellitus (T2DM) patients, and to identify key determinants of treatment‐mediated glycated haemoglobin (HbA1c) reduction. Materials and methods: Glycaemic control during dapagliflozin treatment was mechanistically characterized by integrating components representing dapagliflozin pharmacokinetics (PK), glucose‐insulin homeostasis, renal glucose reabsorption, and HbA1c formation. The model was developed using PK variables, glucose, plasma insulin, and urinary glucose excretion (UGE) from a phase IIa dapagliflozin trial in patients with T2DM (NCT00162305). The model was used to predict dapagliflozin‐induced HbA1c reduction; model predictions were compared to actual data from phase III trials (NCT00528879, NCT00683878, NCT00680745 and NCT00673231). Results: The integrated glucose‐insulin‐dapagliflozin model successfully described plasma glucose and insulin levels, as well as UGE in response to oral glucose tolerance tests and meal intake. HbA1c reduction was also well predicted. The results show that dapagliflozin‐mediated glycaemic control is anticorrelated to steady‐state insulin concentration and insulin sensitivity. Conclusions: The developed model framework is the first to integrate SGLT2 inhibitor mechanism of action with both short‐term glucose‐insulin dynamics and long‐term glucose control (HbA1c). The results suggest that dapagliflozin treatment is beneficial in patients with inadequate glycaemic control from insulin alone and this benefit increases as insulin control diminishes. [ABSTRACT FROM AUTHOR]